Jason Galicia
Internal Medicine · Chambersburg, PANPI 1730333634
Payments from drug & device makers
Across 214 payments — averaging $18.26 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$729
- Novo Nordisk$708
- Pfizer$300
- Amgen$285
- Lilly USA, LLC$284
- GSK$252
- plus $1K from 22 others
What the payments were for
- Food & beverage$3,907100%
- Education$10%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 48 | $729 |
| Novo Nordisk | 35 | $708 |
| Pfizer | 17 | $300 |
| Amgen | 14 | $285 |
| Lilly USA, LLC | 19 | $284 |
| GSK | 13 | $252 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 14 | $215 |
| AstraZeneca | 11 | $178 |
| Abbott | 5 | $102 |
| Boehringer Ingelheim | 1 | $94 |
| Exact Sciences | 3 | $85 |
| Boston Scientific | 1 | $85 |
| Tactile Systems Technology Inc | 5 | $84 |
| Johnson & Johnson | 5 | $81 |
| Cequr Corporation | 2 | $60 |
| Sumitomo Pharma America, Inc. | 4 | $53 |
| Merck | 3 | $49 |
| Phathom Pharmaceuticals, Inc. | 3 | $49 |
| Novartis | 2 | $37 |
| Averitas Pharma Inc. | 1 | $28 |
| Astellas Pharma US Inc | 1 | $22 |
| Daiichi Sankyo Inc. | 1 | $22 |
| Supernus Pharmaceuticals, Inc. | 1 | $21 |
| Insightec,inc | 1 | $20 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $18 |
| Tetraphase Pharmaceuticals, Inc. | 1 | $16 |
| E.r. Squibb & Sons, L.L.C. | 1 | $15 |
| Idorsia Pharmaceuticals US Inc | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$3,908 in reported general payments places this provider in the 85th percentile of 5,705 internal medicine providers in Pennsylvania.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 105 | $110,913 |
| TrulicityDulaglutide | 54 | $92,402 |
| OzempicSemaglutide | 63 | $85,812 |
| JardianceEmpagliflozin | 43 | $59,739 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 76 | $47,358 |
| XifaxanRifaximin | 11 | $42,346 |
| FarxigaDapagliflozin Propanediol | 41 | $40,373 |
| MounjaroTirzepatide | 22 | $40,193 |
| Repatha SureclickEvolocumab | 55 | $34,534 |
| Nurtec OdtRimegepant Sulfate | 13 | $25,555 |
| RybelsusSemaglutide | 13 | $23,635 |
| XareltoRivaroxaban | 15 | $18,280 |
| Breo ElliptaFluticasone/Vilanterol | 28 | $14,159 |
| LinzessLinaclotide | 14 | $11,773 |
| Combivent RespimatIpratropium/Albuterol Sulfate | 14 | $11,555 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis, Nurtec Odt | $300 | $136,468118 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $284 | $132,59576 claims |
| Novo NordiskOzempic, Rybelsus | $708 | $109,44776 claims |
| Boehringer IngelheimJardiance, Combivent Respimat | $94 | $71,29357 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Incruse Ellipta | $252 | $66,047117 claims |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan | $215 | $42,34611 claims |
| AstraZenecaFarxiga | $178 | $40,37341 claims |
| Johnson & JohnsonXarelto | $81 | $18,28015 claims |
| AbbVieLinzess | $729 | $11,77314 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 5,705 internal medicine providers in Pennsylvania.
Other internal medicine in Chambersburg
- Jonathan EpsteinPhiladelphia$13.1M
- Siddharth ShethPittsburgh$11M
- Nathan PatelTannersville$9.5M
- Pitamber DevgonPhiladelphia$7.5M
- Christopher StillDanville$7.1M
- Liza VillaruzPittsburgh$6.6M
- Paul HartleyUniontown$4.9M
- Victor KoladeSayre$4.7M
- Michael OliverBeaver$4.7M
- Raman PurighallaPittsburgh$3.9M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.